Glucose Biosensors Market Report 2025

The glucose biosensors market size has grown rapidly in recent years. It will grow from $15.26 billion in 2024 to $16.85 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to research and development, cost-efficiency, user-friendly design, increasing diabetes prevalence, integration with smart devices, non-invasive monitoring techniques.

The glucose biosensors market size is expected to see rapid growth in the next few years. It will grow to $27.54 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to personalized healthcare solutions, rise in diabetes cases, continuous glucose monitoring expansion, integration with wearable tech, non-invasive monitoring development. Major trends in the forecast period include eco-friendly biosensor designs, interconnectivity and data sharing, home healthcare empowerment, non-invasive monitoring techniques, implantable biosensors.

The increasing prevalence of diabetes is projected to drive the growth of the glucose biosensors market in the coming years. Diabetes is a chronic condition that occurs when the pancreas does not produce sufficient insulin or when the body is unable to effectively use the insulin produced. Patients with diabetes rely on glucose biosensors to regularly monitor their blood glucose levels, allowing them to manage their condition more effectively and adjust their medication as needed. For example, in June 2024, NHS England, a governing body in the UK, reported that in 2023, 3,615,330 individuals registered with a GP were identified as having non-diabetic hyperglycemia, commonly known as pre-diabetes, which reflects an increase from 3,065,825 in 2022 - an almost 18% rise. Therefore, the growing prevalence of diabetes is a significant factor driving the expansion of the glucose biosensors market.

The increasing aging population is anticipated to contribute to the growth of the glucose biosensor market. The aging population, characterized by a rising proportion of elderly individuals, benefits from glucose biosensors that support effective diabetes management through early detection, remote monitoring, and overall well-being. According to the World Health Organization's October 2022 report, globally, one in six people will be 60 or older by 2030, with the number of individuals in this age group reaching 2.1 billion by 2050. In the United Kingdom, projections from the UK Parliament's House of Commons Library in June 2021 indicate that by 2043, the senior population will constitute 24% of the total population, amounting to 17.4 million people. Therefore, the growing aging population is a significant factor driving the growth of the glucose biosensor market.

Leading companies in the glucose biosensor market are concentrating on innovative product launches, particularly glucose monitoring systems, to assist individuals with diabetes. These systems are designed to continuously measure and provide real-time data on blood glucose levels, helping individuals manage their condition more effectively. For instance, in October 2024, DexCom Inc., a biotechnology company based in the United States, introduced the Stelo Glucose Biosensor System. This system is notable for being the first over-the-counter (OTC) continuous glucose monitor (CGM) approved by the U.S. Food and Drug Administration (FDA). The Stelo system is intended for adults aged 18 and older who do not use insulin, including those with Type 2 diabetes or prediabetes. It can also be utilized by individuals without diabetes who want to monitor their glucose levels to better understand how their diet and exercise impact blood sugar.

Major companies in the glucose biosensor market are emphasizing innovative product launches, exemplified by the introduction of the GlucoMen Day continuous glucose monitoring (CGM) system, to diversify their product portfolio and broaden market outreach. The GlucoMen Day CGM system, a real-time subcutaneous continuous glucose monitoring system, is designed to assist individuals with diabetes in effectively managing their blood sugar levels. This system offers a more convenient and accurate alternative for tracking glucose fluctuations compared to traditional finger-pricking methods. In April 2022, 77 Elektronika Kft., a Hungary-based medical equipment manufacturer, introduced the glucomen day continuous glucose monitoring (CGM) system in collaboration with A. Menarini Diagnostics, an Italy-based diagnostics company. The glucomen day CGM system represents a notable advancement in diabetes management technology, providing users with valuable insights into their glucose levels and empowering them to make informed decisions for better diabetes control. This innovative system has the potential to enhance the quality of life for people with diabetes and alleviate the burden of this chronic condition.

In May 2023, Medtronic plc, an Ireland-based medical device company, completed the acquisition of EOFLOW Co., Ltd. for $738 million. Through this strategic acquisition, Medtronic plc aims to broaden treatment options, cater to the demand for discreet delivery, and strengthen its position in the market. EOFLOW Co. Ltd. is a South Korea-based medical device company specialized in developing and manufacturing wearable drug delivery systems.

Major companies operating in the glucose biosensors market include Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, GlySens Incorporated, Trividia Health, Bayer AG, LifeScan Inc., Medtronic plc, Nova Biomedical Corporation, Senseonics Holdings, ACON Laboratories Inc., AgaMatrix Inc., Ypsomed AG, Ascencia Diabetes Care Holdings Inc., Bio-Rad Laboratories Inc., DuPont de Nemours Inc., Biosensors International Group Ltd., Cytiva, Universal Biosensors Inc., CARDEA BIO INC., Conductive Technologies Inc., EarlySense Inc., Innovative Sensor Technology IST AG, LifeSignals Inc., NeuroSky Inc., SD Biosensor INC., Xsensio, Taidoc Technology Corporation.

North America was the largest region in the glucose biosensors market in 2024. The regions covered in the glucose biosensors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glucose biosensors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A glucose biosensor is a specialized device designed for measuring glucose levels in different samples, commonly found in biological fluids such as blood or interstitial fluid. Widely applied in healthcare, especially for diabetes management, these biosensors facilitate convenient and frequent monitoring of blood glucose levels.

The primary product categories for glucose biosensors include continuous glucose monitoring, self-monitoring blood glucose, and non-invasive glucose monitoring. Continuous glucose monitoring (CGM) involves using a miniature sensor implanted under the skin to measure glucose levels in the patient's body. This method offers a more comprehensive view of glucose levels compared to standard fingerstick glucose monitoring and provides real-time results. The technologies predominantly used are electrochemical biosensors, optical biosensors, piezoelectric biosensors, and others. These biosensors find applications across various end-users such as hospitals, home care, diagnostic centers, clinics, and others.

The glucose biosensors market research report is one of a series of new reports that provides glucose biosensors market statistics, including glucose biosensors industry global market size, regional shares, competitors with a glucose biosensors market share, detailed glucose biosensors market segments, market trends and opportunities, and any further data you may need to thrive in the glucose biosensors industry. This glucose biosensors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glucose biosensors market consists of sales of magnetic biosensors, thermometric biosensors, potentiometric, amperometric, and conductometric sensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.